FDA Overhauls Its Purple Book

Searchable Biologics Database Is Welcomed By Biosimilars Industry

The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.

Books
The ‘Purple Book’ Biological Counterpart To The FDA’s ‘Orange Book’ Is Now Searchable • Source: Shutterstock

The US Food and Drug Administration’s ‘Purple Book’ biologics counterpart to its ‘Orange Book’ for small-molecule drugs has been overhauled by the agency to turn it into a searchable database of biologics information.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Biosimilars

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By 

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Discounted Ustekinumab Biosimilars Further Dent J&J’s Q1 Stelara Sales

 

With discounts reaching up to 90%, ustekinumab biosimilars have eroded originator Stelara’s sales as expected. In its latest quarterly biosimilar market report, Samsung Bioepis also analyzed the latest regulatory steps to streamline biosimilar development.

Roche Suggests Perjeta Biosimilars May Not Hit Until 2027 ‘Or Later’

 
• By 

Amid several insights into its expectations of biosimilar competition in 2025, Roche has confirmed the total amount it anticipates being shaved from its top line this year.

How To Make The Most Of Your GGB Awards Entries

 
• By 

With the Global Generics & Biosimilars Awards 2025 taking place in Frankfurt this October, we bring you five key pieces of guidance to help ensure that your entries stand out from the competition.

More from Products